Risk factors for NRM 6 months from GVHD treatment
| . | Without biomarker severity . | With biomarker severity . | ||
|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Time of GVHD onset | ||||
| Classic | 1 | Ref | 1 | Ref |
| Late | 0.7(2 0.49-1.07) | .100 | 0.87 (0.53-1.42) | .580 |
| Clinical GVHD severity | ||||
| Grades 1/2 | 1 | Ref | 1 | Ref |
| Grades 3/4 | 3.23 (2.44-4.29) | <.001 | 2.24 (1.59-3.16) | <.001 |
| Biomarker severity | ||||
| AA 1 | 1 | Ref | ||
| AA 2/3 | 3.52 (2.48-4.99) | < .001 | ||
| Recipient age (y), category | ||||
| <55 | 1 | Ref | 1 | Ref |
| ≥55 | 2.47 (1.64-3.72) | < .001 | 2.22 (1.42-3.48) | < .001 |
| Sex mismatch | ||||
| Other | 1 | Ref | 1 | Ref |
| Female-to-male | 1.16 (0.82-1.63) | .400 | 1.15 (0.78-1.70) | .490 |
| Primary disease | ||||
| Acute leukemia | 1 | Ref | 1 | Ref |
| MDS/MPN | 1.05 (0.78-1.35) | .870 | 1.01 (0.70-1.47) | .950 |
| Malignant lymphoma | 0.78 (0.46-1.32) | .350 | 1.06 (0.59-1.88) | .850 |
| Other | 1.43 (0.99-2.10) | .060 | 1.47 (0.92-2.34) | .110 |
| Disease risk | ||||
| Standard | 1 | Ref | 1 | Ref |
| High | 1.23 (0.88-1.72) | .230 | 1.03 (0.69-1.52) | .890 |
| Donor type | ||||
| HLA-MRD | 1 | Ref | 1 | Ref |
| HLA-MUD | 1.20 (0.84-1.70) | .320 | 1.20 (0.79-1.82) | .400 |
| HLA-MMUD | 1.61 (0.92-2.82) | .094 | 1.87 (0.99-3.55) | .054 |
| Haploidenticaldonor | 1.06 (0.48-2.31) | .890 | 0.86 (0.35-2.08) | .740 |
| GVHD prophylaxis | ||||
| CNI and MTX based | 1 | Ref | 1 | Ref |
| CNI and MMF based | 0.83 (0.57-1.20) | .310 | 0.74 (0.49-1.12) | .160 |
| PTCy | 0.67 (0.37-1.23) | .200 | 0.69 (0.37-1.32) | .260 |
| Other | 0.83 (0.42-1.65) | .600 | 0.89 (0.43-1.86) | .760 |
| HCT-CI | ||||
| 0-2 | 1 | Ref | 1 | Ref |
| ≥3 | 1.26 (0.95-1.66) | .110 | 1.23 (0.89-1.69) | .210 |
| In vivo T-cell depletion | ||||
| No | 1 | Ref | 1 | Ref |
| Yes | 0.80 (0.58-1.11) | .180 | 0.75 (0.52-1.07) | .110 |
| Donor source | ||||
| Bone marrow | 1 | Ref | 1 | Ref |
| Peripheral blood | 0.77 (0.53-1.14) | .190 | 0.83 (0.55-1.27) | .390 |
| Conditioning | ||||
| MAC (TBI < 8 Gy) | 1 | Ref | 1 | Ref |
| MAC (TBI ≥ 8 Gy) | 0.89 (0.49-1.62) | .710 | 0.90 (0.47-1.70) | .730 |
| RIC | 1.42 (1.05-1.93) | .024 | 1.52 (1.06-2.16) | .021 |
| Year of HCT | 0.99 (0.92-1.06) | .730 | 0.97 (0.90-1.06) | .520 |
| . | Without biomarker severity . | With biomarker severity . | ||
|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Time of GVHD onset | ||||
| Classic | 1 | Ref | 1 | Ref |
| Late | 0.7(2 0.49-1.07) | .100 | 0.87 (0.53-1.42) | .580 |
| Clinical GVHD severity | ||||
| Grades 1/2 | 1 | Ref | 1 | Ref |
| Grades 3/4 | 3.23 (2.44-4.29) | <.001 | 2.24 (1.59-3.16) | <.001 |
| Biomarker severity | ||||
| AA 1 | 1 | Ref | ||
| AA 2/3 | 3.52 (2.48-4.99) | < .001 | ||
| Recipient age (y), category | ||||
| <55 | 1 | Ref | 1 | Ref |
| ≥55 | 2.47 (1.64-3.72) | < .001 | 2.22 (1.42-3.48) | < .001 |
| Sex mismatch | ||||
| Other | 1 | Ref | 1 | Ref |
| Female-to-male | 1.16 (0.82-1.63) | .400 | 1.15 (0.78-1.70) | .490 |
| Primary disease | ||||
| Acute leukemia | 1 | Ref | 1 | Ref |
| MDS/MPN | 1.05 (0.78-1.35) | .870 | 1.01 (0.70-1.47) | .950 |
| Malignant lymphoma | 0.78 (0.46-1.32) | .350 | 1.06 (0.59-1.88) | .850 |
| Other | 1.43 (0.99-2.10) | .060 | 1.47 (0.92-2.34) | .110 |
| Disease risk | ||||
| Standard | 1 | Ref | 1 | Ref |
| High | 1.23 (0.88-1.72) | .230 | 1.03 (0.69-1.52) | .890 |
| Donor type | ||||
| HLA-MRD | 1 | Ref | 1 | Ref |
| HLA-MUD | 1.20 (0.84-1.70) | .320 | 1.20 (0.79-1.82) | .400 |
| HLA-MMUD | 1.61 (0.92-2.82) | .094 | 1.87 (0.99-3.55) | .054 |
| Haploidenticaldonor | 1.06 (0.48-2.31) | .890 | 0.86 (0.35-2.08) | .740 |
| GVHD prophylaxis | ||||
| CNI and MTX based | 1 | Ref | 1 | Ref |
| CNI and MMF based | 0.83 (0.57-1.20) | .310 | 0.74 (0.49-1.12) | .160 |
| PTCy | 0.67 (0.37-1.23) | .200 | 0.69 (0.37-1.32) | .260 |
| Other | 0.83 (0.42-1.65) | .600 | 0.89 (0.43-1.86) | .760 |
| HCT-CI | ||||
| 0-2 | 1 | Ref | 1 | Ref |
| ≥3 | 1.26 (0.95-1.66) | .110 | 1.23 (0.89-1.69) | .210 |
| In vivo T-cell depletion | ||||
| No | 1 | Ref | 1 | Ref |
| Yes | 0.80 (0.58-1.11) | .180 | 0.75 (0.52-1.07) | .110 |
| Donor source | ||||
| Bone marrow | 1 | Ref | 1 | Ref |
| Peripheral blood | 0.77 (0.53-1.14) | .190 | 0.83 (0.55-1.27) | .390 |
| Conditioning | ||||
| MAC (TBI < 8 Gy) | 1 | Ref | 1 | Ref |
| MAC (TBI ≥ 8 Gy) | 0.89 (0.49-1.62) | .710 | 0.90 (0.47-1.70) | .730 |
| RIC | 1.42 (1.05-1.93) | .024 | 1.52 (1.06-2.16) | .021 |
| Year of HCT | 0.99 (0.92-1.06) | .730 | 0.97 (0.90-1.06) | .520 |
Clinical and biomarker severity were evaluated at the time of GVHD treatment.
The number of events in this model was 217.
HCT-CI, HCT-specific comorbidity index; MDS/MPN, myelodysplastic syndromes/myeloproliferative neoplasms; MMF, mycophenolate mofetil; MTX, methotrexate; TBI, total body irradiation.